1. World Health Organization. Global Tuberculosis Report 2016. WHO/HTM/TB/2016.13. Geneva, World Health Organization, 2016. http://apps.who.int/medicinedocs/documents/s23098en/s23098en.pdf
2. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004;Bloss;Int J Tuberc Lung Dis,2010
3. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
4. US Food and Drug Administration (FDA). Drug Approval Package. SIRTURO (bedaquiline) 100 mg Tablets. Company: Janssen Research and Development, LLC. Application No. 204384. www.accessdata.fda.gov/drugsatfda_docs/nda/2012/204384Orig1s000TOC.cfm Approval date: December 28, 2012. Date last accessed: February 19, 2018.
5. European Medicines Agency. European public assessment report (EPAR) summary for the public. Deltyba (delamanid). London, European Medicines Agency, 2014. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002552/WC500166235.pdf